Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

EMA Recommends Granting a Conditional Marketing Authorisation for Cemiplimab

It is indicated for the treatment of advanced cutaneous squamous cell carcinoma
30 Apr 2019
Skin Cancers

On 26 April 2019, the European Medicines Agency’s (EMA’s) Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommending the granting of a conditional marketing authorisation for the medicinal product cemiplimab (Libtayo), intended for the treatment of advanced cutaneous squamous cell carcinoma.

The applicant for this medicinal product is Regeneron Ireland U.C.

Libtayo will be available as a 350 mg concentrate for solution for infusion. The active substance of Libtayo is cemiplimab, an antineoplastic agent that binds to the programmed cell death-1 (PD-1) receptor and blocks its interaction with its ligands PD-L1 and PD-L2.

The benefits with Libtayo are its ability to reduce tumour size and to prevent progression of the tumour for longer compared to historical controls from the literature in adult patients with locally advanced or metastatic cutaneous squamous cell carcinoma.

The most common side effects are rash, fatigue, diarrhoea and pruritus. The most common immune-related side effects are hypothyroidism, pneumonitis, skin adverse reactions, hyperthyroidism and hepatitis.

The full indication is: Libtayo as monotherapy is indicated for the treatment of adult patients with metastatic or locally advanced cutaneous squamous cell carcinoma who are not candidates for curative surgery or curative radiation.

Detailed recommendations for the use of this product will be described in the summary of product characteristics, which will be published in the European public assessment report and made available in all official European Union languages after the marketing authorisation has been granted by the European Commission.

Summaries of positive opinion are published without prejudice to the European Commission decision, which will normally be issued 67 days from adoption of the opinion.

A conditional marketing authorisation is granted to a medicinal product that fulfils an unmet medical need when the benefit to public health of immediate availability outweighs the risk inherent in the fact that additional data are still required. The marketing authorisation holder is likely to provide comprehensive clinical data at a later stage.

Last update: 30 Apr 2019

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.